Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer

References

• AttardGParkerCEelesRAProstate cancerLancet201638710013708226074382
   PubMed Web of Science ®Google Scholar
• LiZAlyamaniMLiJRedirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapyNature2016533760454755127225130
   PubMed Web of Science ®Google Scholar
• SharifiNMechanisms of androgen receptor activation in castration-resistant prostate cancerEndocrinology2013154114010401724002034
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFAFFIRM InvestigatorsIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• ConnPMCrowleyWFJrGonadotropin-releasing hormone and its analoguesN Engl J Med1991324931031984190
   PubMed Web of Science ®Google Scholar
• LeporHComparison of single-agent androgen suppression for advanced prostate cancerRev Urol20057suppl 1S3S12
   Google Scholar
• WaxmanJManAHendryWFImportance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancerBr Med J1985291138713882933122
   PubMed Web of Science ®Google Scholar
• ThompsonIMZeidmanEJRodriguezFRSudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostateJ Urol19901446147914802122011
   PubMed Web of Science ®Google Scholar
• KlotzLBoccon-GibodLShoreNDThe efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerBJU Int2008102111531153819035858
   PubMed Web of Science ®Google Scholar
• EzakiTKosakaTMizunoREfficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonistCancer Chemother Pharmacol201576230130626055219
   PubMed Web of Science ®Google Scholar
• TombalBMillerKBoccon-GibodLAdditional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristicsEur Urol201057583684219962227
   PubMed Web of Science ®Google Scholar
• ZattoniFProstate cancer: what are the news in hormonal therapy? The role of GnRH antagonistsArch Ital Urol Androl201284311111623210401
   PubMedGoogle Scholar
• Boccon-GibodLvan der MeulenEPerssonBEAn update on the use of gonadotropin-releasing hormone antagonists in prostate cancerTher Adv Urol20113312714021904569
   PubMedGoogle Scholar
• SatoTMatsumotoTYamadaTWatanabeTKawanoHKatoSLate onset of obesity in male androgen receptor-deficient (AR KO) miceBiochem Biophys Res Commun2003300116717112480537
   PubMed Web of Science ®Google Scholar
• MatsumotoTSakariMOkadaMThe androgen receptor in health and diseaseAnnu Rev Physiol20137520122423157556
   PubMed Web of Science ®Google Scholar
• KeatingNLO’MalleyAJFreedlandSJSmithMRDoes comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?Eur Urol201364115916622537796
   PubMed Web of Science ®Google Scholar
• CrawfordEDShoreNDMoulJWLong-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelixUrology20148351122112824661333
   PubMed Web of Science ®Google Scholar
• KlotzLMillerKCrawfordEDDisease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonistsEur Urol20146661101110824440304
   PubMed Web of Science ®Google Scholar
• AlbertsenPCKlotzLTombalBGradyJOlesenTKNilssonJCardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonistEur Urol201465356557324210090
   PubMed Web of Science ®Google Scholar
• CollierAMatthewsDMKellettHAClarkeBFHunterJAChange in skin thickness associated with cheiroarthropathy in insulin dependent diabetes mellitusBr Med J19862929363083946
   PubMed Web of Science ®Google Scholar
• RichardsonTKerrDSkin-related complications of insulin therapy: epidemiology and emerging management strategiesAm J Clin Dermatol200341066166714507228
   PubMed Web of Science ®Google Scholar
• CrowtherMAWarkentinTEBleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood2008111104871487918309033
   PubMed Web of Science ®Google Scholar
• EikelboomJWWallentinLConnollySJRisk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialCirculation2011123212363237221576658
   PubMed Web of Science ®Google Scholar
• D’AmicoAVWhittingtonRMalkowiczSBBiochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerJAMA1998280119699749749478
   PubMed Web of Science ®Google Scholar
• TajimaMNodaMOrigasaHEvidence-based practice guideline for the treatment for diabetes in Japan 2013Diabetol Int20156151187
   Web of Science ®Google Scholar
• OrtelTLPerioperative management of patients on chronic antithrombotic therapyBlood2012120244699470522855600
   PubMed Web of Science ®Google Scholar
• NomuraSGilmourSTsubokuraMMortality risk amongst nursing home residents evacuated after the Fukushima nuclear accident: a retrospective cohort studyPLoS One201383e6019223555921
   PubMed Web of Science ®Google Scholar
• NomuraSBlangiardoMTsubokuraMPost-nuclear disaster evacuation and survival amongst elderly people in Fukushima: a comparative analysis between evacuees and non-evacueesPrev Med201682778226592687
   PubMed Web of Science ®Google Scholar
• MillerLRPartinAWChanDWInfluence of radical prostatectomy on serum hormone levelsJ Urol199816024494539679896
   PubMed Web of Science ®Google Scholar
• OlssonMEkströmLSchulzeJRadical prostatectomy: influence on serum and urinary androgen levelsProstate201070220020519760638
   PubMed Web of Science ®Google Scholar
• LacknerJEMaerkIKollerASerum inhibin – not a cause of low testosterone levels in hypogonadal prostate cancer?Urology2008721121112418407338
   PubMed Web of Science ®Google Scholar
• KarunasingheNMastersJFlanaganJUFergusonLRInfluence of Aldo-keto reductase 1C3 in prostate cancer – a mini reviewCurr Cancer Drug Targets201717760361628359237
   PubMed Web of Science ®Google Scholar
• KarunasingheNZhuYHanDYQuality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?BMC Urol20161614827485119
   PubMed Web of Science ®Google Scholar